Would you use perioperative durvalumab in patients with diffuse-type gastric adenocarcinoma given no event-free survival benefit was seen for these patients in MATTERHORN?

Although MATTERHORN demonstrated a significant event-free survival benefit for perioperative durvalumab plus FLOT in the overall population, the forest plot does not show a clearly favorable signal in the diffuse-type subgroup. Because subgroup analyses are underpowered and not intended to confirm l...

I interpret subgroup analyses with a significant grain of salt. When I see a lack of benefit in a subgroup compared to a significant benefit in the overall population, I ask the question: What is different about this subgroup in the control arm versus the experimental arm? This question is sometimes...